Natalizumab

Generic Name
Natalizumab
Brand Names
Tysabri, Tyruko
Drug Type
Biotech
Chemical Formula
-
CAS Number
189261-10-7
Unique Ingredient Identifier
3JB47N2Q2P
Background

Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for mu...

Indication

Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
...

Associated Conditions
Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Severe Crohn's Disease, Moderate Crohn’s Disease
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath